Literature DB >> 21440698

Breast cancer imaging devices.

Renee M Moadel1.   

Abstract

Conventional mammography is a screening procedure constrained by low specificity in the detection of breast cancer. Approximately 40% of women undergoing mammography screening have dense breast tissue, and conventional mammographic imaging has a sensitivity range of only 50%-85% for malignant lesions. Magnetic resonance imaging (MRI) is now recommended for breast cancer screening in high-risk patients. However, approximately 15% of patients cannot tolerate MRI. These are the clinical situations in which positron emission mammography (PEM) and breast-specific gamma (BSG) camera systems fulfill a need for primary breast cancer imaging. Because breast cancer is the most common malignancy and the second most common cause of cancer death among women, many nuclear medicine imaging techniques are essential in the evaluation and therapy of patients with this disease. Nuclear medicine surgical techniques consist of sentinel lymph node localization and the use of radiolabeled seeds for intraoperative localization of nonpalpable breast cancers. The Food and Drug Administration (FDA) has approved the PEM Flex Solo II scanner, which has the capability for stereotactic biopsy, with an array of pixelated lutetium yttrium orthosilicate (LYSO) crystals, position-sensitive photomultiplier tubes (PS-PMT), and a spatial resolution of 2.4 mm. Clear PEM is a scanner in development with cerium-doped LYSO (LYSO:Ce) crystals, multipixel avalanche photodiodes, depth of interaction measurement with a resolution of 1.3 mm. The Dilon 6800 Gamma Camera is a BSG device approved by the FDA with stereotactic biopsy guidance capability, a pixelated array of sodium iodide crystals, PS-PMTs, and an extrinsic spatial resolution of 6 mm at 3 cm from the camera. GE has just received clearance from the FDA for a molecular breast imaging camera, the Discovery NM 750 b, with pixelated cadmium zinc telluride crystals, semiconductor photoelements and an extrinsic resolution of 3.5 mm at 3 cm. The Society of Nuclear Medicine has issued guidelines for BSG camera image interpretation recommendations and clinical indications. Different crystals and camera architectures are under investigation to further improve resolution for both PEM and BSG imaging.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21440698     DOI: 10.1053/j.semnuclmed.2010.12.005

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  9 in total

1.  VPAC1 receptors for imaging breast cancer: a feasibility study.

Authors:  Mathew L Thakur; Kaijun Zhang; Adam Berger; Barbara Cavanaugh; Sung Kim; Chaitra Channappa; Andrea J Frangos; Eric Wickstrom; Charles M Intenzo
Journal:  J Nucl Med       Date:  2013-05-07       Impact factor: 10.057

Review 2.  Nuclear imaging of the breast: translating achievements in instrumentation into clinical use.

Authors:  Carrie B Hruska; Michael K O'Connor
Journal:  Med Phys       Date:  2013-05       Impact factor: 4.071

Review 3.  The Evolving Role of FDG-PET/CT in the Diagnosis, Staging, and Treatment of Breast Cancer.

Authors:  Koosha Paydary; Siavash Mehdizadeh Seraj; Mahdi Zirakchian Zadeh; Sahra Emamzadehfard; Sara Pourhassan Shamchi; Saeid Gholami; Thomas J Werner; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2019-02       Impact factor: 3.488

4.  Design and characterization of a low profile NaI(Tl) gamma camera for dedicated molecular breast tomosynthesis.

Authors:  Andrew M Polemi; Justin Niestroy; Alexander Stolin; Gangadhar Jaliparthi; Randy Wojcik; Stan Majewski; Mark B Williams
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2016-10-03

5.  Immunophenotyping invasive breast cancer: paving the road for molecular imaging.

Authors:  Jeroen F Vermeulen; Aram S A van Brussel; Petra van der Groep; Folkert H M Morsink; Peter Bult; Elsken van der Wall; Paul J van Diest
Journal:  BMC Cancer       Date:  2012-06-13       Impact factor: 4.430

6.  Kinetic Curve Type Assessment for Classification of Breast Lesions Using Dynamic Contrast-Enhanced MR Imaging.

Authors:  Shih-Neng Yang; Fang-Jing Li; Jun-Ming Chen; Geoffrey Zhang; Yen-Hsiu Liao; Tzung-Chi Huang
Journal:  PLoS One       Date:  2016-04-07       Impact factor: 3.240

Review 7.  Methodological aspects of 99mTc-sestamibi guided biopsy in breast cancer.

Authors:  A Collarino; R A Valdés Olmos; A F van der Hoeven; L M Pereira Arias-Bouda
Journal:  Clin Transl Imaging       Date:  2016-07-16

8.  Breast cancer detected as an incidental finding on 99mTc-MIBI scintigraphy.

Authors:  Toshihiro Homma; Osamu Manabe; Kazuomi Ichinokawa; Hiroko Yamashita; Noriko Oyama-Manabe; Fumi Kato; Kenji Hirata; Markus Kroenke; Nagara Tamaki
Journal:  Acta Radiol Open       Date:  2017-07-25

Review 9.  The role of general nuclear medicine in breast cancer.

Authors:  Lacey R Greene; Deborah Wilkinson
Journal:  J Med Radiat Sci       Date:  2015-02-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.